Latest news with #LiveEventsCompany
Time of India
6 days ago
- Business
- Time of India
Indian pharma on alert as US mulls higher drug tariffs
Indian drug makers are weighing the possible fallout of additional reciprocal tariffs imposed by the US in response to the country's oil purchases from Russia. Earlier, the Trump administration had imposed a 25% tariff effective August 1 but it had spared pharmaceutical products from India. Experts said the tariffs are held back on pharma imports due to the ongoing investigation by the US government related to imports of pharmaceutical products and national security under Section 232 of the Trade Expansion Act, 1962. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Sources in the pharma industry said the same situation may prevail but they said there is an air of uncertainty given the frequent changes in the structure, prompting drug makers to look at mitigation strategies. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Orthopedic Knee Surgeon: Suffering From Pain After Age 50? Do This Every Morning Wellnee Undo Over its first quarter earnings call with investors on Wednesday, Lupin CEO Vinita Gupta said, "It is hard to predict where this (tariff) lands". But she added the company has considered price flexibility to offset the impact of tariffs. She also noted the possibility of a tech transfer into the US to cut the tariff impact. Alluding to President Trump's most recent hints at a 10-15% tariff on pharma imports, she said, "I think it will be fairly manageable. In any case the question is whether it is 25% or 150% or 200% kind of numbers that are being floated". Live Events Company executives however noted that the US government will be very conscious about the measures they take because it is about access to medicine and could impact them significantly. Indian Pharmaceutical Alliance secretary general Sudarshan Jain said, "The recent executive order by the US administration excludes the pharmaceutical sector from immediate tariff imposition. The sector is being reviewed under Section 232 investigation". "Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care. India-US partnership is key to securing API supply chains and enhancing healthcare resilience," he said.
Time of India
02-06-2025
- Business
- Time of India
Reliance Power shares rally 5% to hit fresh 52-week high amid volume surge and clean energy order win
Live Events Company's financials Technicals Shareholding structure (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Reliance Power climbed as much as 5.5% on Monday to a record high of Rs 61.38 on the BSE, extending their recent rally driven by strong trading volumes and a major renewable energy project win. The stock has now surged over 17% in the past week and nearly 52% in the past Monday, trading activity remained elevated, with 1,654.71 lakh shares worth Rs 996.13 crore changing hands on the exchanges, indicating continued investor interest. The stock has now gained 56.8% over the last six months and 147% in the past rally follows Friday's sharp jump of nearly 16% when the shares hit a 52-week high of Rs 60.5 on the NSE, also supported by heavy Power's gains have been underpinned by its recent announcement on May 28 that its subsidiary, Reliance NU Energies, secured a Letter of Award (LOA) for a 350 MW inter-state transmission system (ISTS)-connected solar power project coupled with a 175 MW/700 MWh Battery Energy Storage System (BESS) from SJVN , a Navratna public sector NU Energies had earlier emerged as the successful bidder in the auction for the project at a fixed tariff of Rs 3.33/kWh for 25 years.'The project was part of a larger 1,200 MW solar + 600 MW/2,400 MWh BESS tender, which attracted participation from 19 developers, with 18 qualifying for the final e-reverse auction. The tender was oversubscribed by more than 4 times, reflecting heightened industry interest in dispatchable renewable energy solutions,' the company project will add 600 MW of solar DC capacity and 700 MWh of BESS capacity to Reliance Power's portfolio. With this, the company now has a clean energy pipeline of 2.4 GW of Solar DC and over 2.5 GWh of BESS capacity.'The project reinforces Reliance Power's strategic commitment to renewable energy leadership, while delivering sustainable value creation across stakeholders. It marks a significant milestone in the company's strategic vision to transition toward cleaner energy sources and play a pivotal role in shaping the country's sustainable energy future,' the company the January–March quarter of FY25, Reliance Power reported a consolidated net profit of Rs 126 crore, reversing a loss of Rs 397.56 crore in the same period last year. This turnaround was primarily driven by a steep reduction in expenses, which dropped to Rs 1,998.49 crore from Rs 2,615.15 crore a year earlier, even as revenue fell slightly to Rs 2,066 the full year, the company posted a net profit of Rs 2,947.83 crore, compared to a loss of Rs 2,068.38 crore in Power also said it completed debt servicing of Rs 5,338 crore over the past 12 months, including maturity repayments, bringing down its debt-to-equity ratio to 0.88:1 in FY25 from 1.61:1 in a technical perspective, Reliance Power shares are currently trading above all key moving averages — from the 5-day to the 200-day simple moving average — indicating bullish Relative Strength Index (RSI) stands at 76.9, placing the stock in overbought territory and potentially signalling a pullback. Meanwhile, the MACD is at 3.4 and remains above both the centre and signal line, reinforcing the ongoing bullish of May 7, 2025, promoters held 24.98% of Reliance Power's shares. Foreign institutional investors (FIIs) held 12.87%, mutual funds 0.37%, and other institutions 16.1%.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
